Nevro Corp. (NYSE:NVRO) Receives Daily Media Sentiment Score of 0.22

News coverage about Nevro Corp. (NYSE:NVRO) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Nevro Corp. earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.5261597410124 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Nevro Corp. (NYSE:NVRO) traded up 1.27% during midday trading on Friday, hitting $81.90. 303,020 shares of the stock were exchanged. The firm’s market capitalization is $2.41 billion. The firm’s 50-day moving average price is $82.27 and its 200 day moving average price is $85.24. Nevro Corp. has a 1-year low of $65.82 and a 1-year high of $106.93.

Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.11. The business had revenue of $78.02 million during the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period last year, the company earned ($0.31) earnings per share. Analysts expect that Nevro Corp. will post ($1.17) earnings per share for the current fiscal year.

Several analysts have issued reports on NVRO shares. B. Riley downgraded Nevro Corp. from a “buy” rating to a “neutral” rating and dropped their price target for the company from $108.00 to $85.00 in a research note on Tuesday, May 9th. Northland Securities reissued a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a research note on Tuesday, May 9th. Zacks Investment Research cut Nevro Corp. from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. ValuEngine cut Nevro Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, May 24th. Finally, J P Morgan Chase & Co restated an “overweight” rating and issued a $102.00 price objective on shares of Nevro Corp. in a report on Monday, July 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $100.57.

TRADEMARK VIOLATION WARNING: “Nevro Corp. (NYSE:NVRO) Receives Daily Media Sentiment Score of 0.22” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.baseball-news-blog.com/2017/08/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-nevro-corp-nysenvro-stock-price-updated-updated.html.

In related news, CFO Andrew H. Galligan sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $75.30, for a total value of $564,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 12.10% of the company’s stock.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply